# Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

> **NCT02005458** · PHASE2 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 80 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Breast Cancer

## Interventions

- **DRUG:** YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- **DRUG:** YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- **DRUG:** YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle
- **DRUG:** PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle

## Key facts

- **NCT ID:** NCT02005458
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2017-03
- **Final completion:** 2018-02
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02005458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02005458, "Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02005458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*